TG Therapeutics Inc

NASDAQ:TGTX   11:20:17 AM EDT
4.29
-0.11 (-2.50%)
Products

TG Therapeutics Announces FDA Extension Of BLA PDUFA Date For Ublituximab To Treat Patients With RMS

Published: 05/31/2022 11:55 GMT
TG Therapeutics Inc (TGTX) - Tg Therapeutics Announces FDA Extension of Bla PDUFA Date for Ublituximab to Treat Patients With Rms.
Tg Therapeutics Inc - FDA Has Extended PDUFA Goal Date to December 28, 2022.
Tg Therapeutics Inc - FDA Extended PDUFA Goal Date to Allow Time to Review a Submission Provided by Company in Response to an FDA Information Request.
Tg Therapeutics Inc - Submission Comprised an Integration and Summary of Certain Clinical Information That Was Previously Provided to FDA by Company.